新型冠狀病毒（SARS-CoV-2）傳染性強，病死率高，目前無有效的治療方法。病毒主要侵襲患者的肺部，重癥患者多因合并急性呼吸窘迫綜合征、膿毒癥休克等導致多器官功能衰竭。新型冠狀病毒肺炎（COVID-19）的進展程度與患者的免疫狀態(tài)密切相關，烏司他丁可以有效抑制炎性因子的釋放及改善免疫狀況，臨床應用可降低急性呼吸窘迫綜合征及膿毒癥患者的死亡率，而且該藥還可以和激素或血必凈聯(lián)合使用，進一步增強臨床療效，且無明顯的不良反應。因此認為烏司他丁用于減輕COVID-19重癥患者的肺損傷有一定的可行性。

New coronavirus (SARS-CoV-2) is highly contagious and has a high fatality rate, and there is no definitive and effective treatment at present. The virus mainly invades the lungs, COVID-19 severe patients have ARDS or septic shock will lead to multiple organ failure. The progression of the new coronavirus pneumonia is closely related to the immune state of patients. Ulinastatin can effectively inhibit the release of inflammatory factors and improve immune status. So we use it to reduce the mortality rate of ARDS and sepsis patients in clinical application. Moreover, Ulinastatin can be used in combination with hormone or Xuebijing to further enhance the clinical efficacy without obvious adverse reactions. So Ulinastatin can be used to reduce the injury in severe COVID-19 patients.

R978.7